We Believe Our Approach Has Created a Leading Pipeline of Multiple Drug and Development Candidates in Targeted Radiopharmaceutical Therapeutics
We have built a portfolio of potential RPT drug and development candidates that includes late-stage clinical programs, development programs and discovery programs. We only file an IND and advance programs beyond IND enabling studies and into formal clinical development once we have conducted rigorous preclinical evaluation and early human imaging studies.
| Target | Drug | Indication | Discovery | IND Enabling | Phase 1 | Phase 2 | Phase 3 | |
|---|---|---|---|---|---|---|---|---|
| SSTR2 | RYZ101 (225Ac) |
|||||||
| RYZ101 (225Ac) |
||||||||
| RYZ101 (225Ac) |
||||||||
| GPC3 | RYZ801(225Ac) RYZ811(68Ga) |
|||||||
| CA9 | Small Molecule | Renal cell cancer (clear cell) | ||||||
| SSTR2 | ||||
|---|---|---|---|---|
| Discovery | IND Enabling | Phase 1 | Phase 2 | Phase 3 | RYZ101 (225Ac) |
| GEP-NETs* | ||||
| RYZ101 (225Ac) |
||||
| ES-SCLC | ||||
| RYZ101 (225Ac) |
||||
| HR+/HER2- Breast Cancer | ||||
| GPC3 | ||||
| Discovery | IND Enabling | Phase 1 | Phase 2 | Phase 3 | RYZ801(225Ac) RYZ811(68Ga) |
| Hepatocellular carcinoma | ||||
| CA9 | ||||
| Discovery | IND Enabling | Phase 1 | Phase 2 | Phase 3 | Small Molecule |
| Renal cell cancer (clear cell) | ||||
*GEP-NETs expressing SSTR2 who are refractory to Lu177 SSA treatment.
